Abilify Asimtufii 960mg Injection – Every-2-Month Care

Abilify Asimtufii 960 mg/3.2 mL is an extended-release injectable suspension for intramuscular use. It contains the active ingredient aripiprazole, an atypical antipsychotic medication used to treat schizophrenia in adults, as well as for the maintenance treatment of bipolar I disorder in adults as monotherapy. Its extended-release formulation allows the medication to be administered once every two months.

What is Abilify Asimtufii used for?

• Helps control the symptoms of schizophrenia in adults.

• Used as monotherapy for the maintenance treatment of bipolar I disorder in adults.

• The extended-release formulation allows dosing every two months instead of daily dosing.

• Contains 960 mg of aripiprazole in 3.2 mL.

• Administered as a single dose every two months, based on the physician’s assessment and the patient’s response to treatment.

How to Use Abilify Asimtufii 960 mg/3.2 mL

• Administered by intramuscular injection into the gluteal muscle only by a physician or qualified healthcare professional. It must not be administered by any other route.

• For patients who have not previously taken aripiprazole, tolerability to aripiprazole should first be established with oral treatment before initiating the extended-release injection.

• The recommended dose is 960 mg once every two months, or 56 days after the previous injection. The physician may reduce the dose to 720 mg every two months if adverse effects occur.

Precautions and Warnings

• Do not use in individuals who are allergic to aripiprazole or any of the ingredients in the formulation.

• It should not be used to treat psychosis associated with dementia in elderly patients, as antipsychotic medications may increase the risk of death in this population.

• May cause involuntary movement disorders, including tardive dyskinesia.

• May cause metabolic changes such as increased blood glucose, diabetes, lipid abnormalities, and weight gain. Therefore, the physician may need to monitor body weight and blood glucose and lipid levels.

• May cause orthostatic hypotension, dizziness, or fainting, particularly in individuals who are dehydrated or have cardiovascular disease.

• Should be used with caution in individuals with a history of seizures.

• May cause drowsiness or impair concentration and motor skills. Caution should therefore be exercised when driving or operating machinery.

• In some cases, it may be associated with compulsive behaviors such as pathological gambling. Patients should inform their physician if unusual behavioral changes occur.

• Inform the physician if you are pregnant, planning to become pregnant, or breastfeeding before using the medication.

Abilify Asimtufii side effects

Common side effects may include:

• Weight gain.

• Restlessness and an uncontrollable need to move (akathisia).

• Injection-site pain or reactions.

• Drowsiness or sedation.

Other symptoms may also occur, such as dizziness, nausea, or insomnia. Potentially serious adverse effects include movement disorders, neuroleptic malignant syndrome, increased blood glucose or lipid abnormalities, hypotension, and fainting.

Drug Interactions

• Aripiprazole levels may be affected when used with medications that influence the hepatic enzymes CYP2D6 and CYP3A4.

• The physician may need to reduce the dose of Abilify Asimtufii to 720 mg every two months when certain strong CYP2D6 or CYP3A4 inhibitors are used for more than 14 days. The medication should be avoided with certain drug combinations, such as the concomitant use of strong CYP2D6 and CYP3A4 inhibitors or strong CYP3A4 inducers.

Therefore, inform your physician or pharmacist about all medications and dietary supplements you are currently taking before receiving the injection.

Storage

• Store at room temperature at 25°C, with permitted excursions between 15°C and 30°C.

• Keep out of reach of children and follow the storage instructions provided on the package.

Ingredients of ABILIFY ASIMTUFII injection

• Active ingredient: Aripiprazole 960 mg/3.2 mL.

• Inactive ingredients: Sodium carboxymethylcellulose, polyethylene glycol 400, povidone, sodium chloride, sodium phosphate monobasic monohydrate, sodium hydroxide for pH adjustment, and water for injection.